1. Home
  2. FLR vs RYTM Comparison

FLR vs RYTM Comparison

Compare FLR & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fluor Corporation

FLR

Fluor Corporation

HOLD

Current Price

$43.24

Market Cap

6.7B

Sector

Industrials

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$90.46

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLR
RYTM
Founded
1912
2008
Country
United States
United States
Employees
N/A
414
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.7B
6.2B
IPO Year
2006
2017

Fundamental Metrics

Financial Performance
Metric
FLR
RYTM
Price
$43.24
$90.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
14
Target Price
$53.50
$131.14
AVG Volume (30 Days)
3.0M
697.4K
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.34
EPS
1.08
N/A
Revenue
$15,503,000,000.00
N/A
Revenue This Year
$6.56
$55.34
Revenue Next Year
$7.10
$86.06
P/E Ratio
$39.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$37.62
$58.71
52 Week High
$57.50
$122.20

Technical Indicators

Market Signals
Indicator
FLR
RYTM
Relative Strength Index (RSI) 37.85 51.87
Support Level $39.93 $79.72
Resistance Level $44.78 $92.17
Average True Range (ATR) 2.08 5.08
MACD -0.79 -0.16
Stochastic Oscillator 12.64 54.39

Price Performance

Historical Comparison
FLR
RYTM

About FLR Fluor Corporation

Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services.It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $15.5 billion in revenue in 2025.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: